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In light of this, it is likely that GWAS hits 
found in intergenic regions far from known 
genes are true associations whose biol-
ogy is not yet understood, rather than 
false positives. The human genome is 
incompletely annotated. Regions where 
GWAS associations have been found, but 
no known genes are located, could easily 
harbor unidentified new genes or regula-
tory elements. For instance, the authors 
point to the colon and prostate cancer risk 
SNP rs693267 located 335 kb upstream 
from the MYC gene on chromosome 8q24 
(McClellan and King, 2010). This locus has 
been shown to physically interact with 
MYC and is associated with enhanced 
Wnt signaling. Therefore, although the biol-
ogy of this locus is not fully understood, 
it suggests a paradigm where intergenic 
disease-associated SNPs alter enhancer 
elements, either directly or through linkage 
disequilibrium, and therefore cause differ-
ential regulation of disease-related genes.
This observation leads to a broader 
point: A lack of biological understanding 
of how these disease-associated vari-
ants are pathogenic does not mean that 
there is no biology to discover. Although 
our understanding of the mechanisms 
by which disease risk loci contribute to 
pathogenesis currently lags behind the 
pace at which new loci are discovered, 
promising stories continue to emerge. To 
continue the previous example, although 
no definitive correlation between the 
rs6983267 genotype and MYC expression 
has been demonstrated, MYC is known to 
be tightly regulated and the right develop-
mental time point may need to be exam-
ined to see such a correlation. Although 
further work is necessary to uncover the 
elusive mechanism by which the SNP 
confers risk, we propose that the existing 
evidence supports rather than refutes this 
SNP as a true cancer risk allele. Another 
example is a non-protein-coding region 
of chromosome 9q21 in which SNPs 
have been robustly associated with arte-
rial disease. A recent paper reported that 
targeted deletion of an orthologous region 
in mouse interferes with cis-regulation of 
nearby genes (Cdkn2a/Cdkn2b) and may 
influence vascular cell proliferation (Visel 
et al., 2010). As a third example, an intronic 
type 2 diabetes risk SNP (rs7903146) was 
recently found to overlap with a region of 
islet cell-selective chromatin, and the two 
alleles of rs7903146 correlate with the 
open/closed chromatin state of the region 
(Gaulton et al., 2010). Thus, understanding 
the mechanisms by which GWAS loci con-
tribute to disease will require considerable 
effort and time. We take this not as a sign 
that the common disease-common vari-
ant model has failed but rather that a chal-
lenge exists for the scientific community—
a challenge that must be addressed with 
both traditional experimental genetics and 
innovative new approaches.
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In a recent Essay published in Cell, 
McClellan and King discussed genetic 
heterogeneity and the potential role of 
rare genetic variants in complex human 
diseases (McClellan and King, 2010). 
These important issues, in particu-
lar the application of high-throughput 
sequencing techniques to discover 
disease genes, are highly relevant to 
genetics researchers. However, the 
authors allocated a substantial propor-
tion of their efforts to being critical of 
the utility of genome-wide association 
studies (GWAS). These particular sec-
tions of the Essay may lead to misin-
terpretation of published studies by us 
and others. For the broad readership of 
Cell and for the scientific community in 
general, we highlight our concerns in 
this Correspondence.
The authors refer to the fact that most 
single-nucleotide polymorphisms (SNPs) 
detected in GWAS reside in intergenic 
regions and consequently challenge the 
utility and reliability of GWAS with the 
question: “How did genome-wide asso-
ciation studies come to be populated by 
strategies for Genetic 
studies of complex Diseases
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risk variants with no known function?” 
When addressed in the proper context, 
however, it is well established that GWAS 
do not attempt to identify functional 
SNPs but rather “tag” the approximate 
location of disease variants, typically 
down to 100 kb or less. This is made 
possible due to the linkage disequilib-
rium (LD) patterns characterized by the 
International HapMap project, that is, the 
correlation of genotypes between the 
yet-to-be-determined underlying disease 
variant and neighboring SNPs. Indeed, 
the vast majority of SNPs used in GWAS 
are of unknown biological function, due 
to the fact that most SNPs reside outside 
of coding regions and that the manufac-
turers of the SNP arrays selected SNPs 
from the HapMap to facilitate efficient 
tagging across the genome, that is, the 
priority was information capture rather 
than putative function. Furthermore, 
noncoding SNPs identified by GWAS 
may reveal intergenic regulatory ele-
ments that are critical to understand, 
and it is now up to the genetics com-
munity to develop approaches to interro-
gate the function of regulatory variants. 
The authors did refer to LD as a potential 
explanation for noncoding variants yield-
ing association in GWAS, but they failed 
to recognize that the design of GWAS is 
not to directly interrogate causal variants 
in the first instance. For example, the two 
GWAS that we have conducted for sickle 
cell anemia and hearing loss (Dickson et 
al., 2010) yielded top hits in intergenic 
regions, but these are in close proximity 
to the causal genes (HBB and GJB2) that 
were already well-established before the 
GWAS era. These studies demonstrate 
the reliability of GWAS for identifying the 
approximate locations of disease genes 
by noncoding SNPs. In addition, they 
represent two vivid examples of how 
GWAS can work by leveraging LD.
McClellan and King have also attrib-
uted many published GWAS hits to 
population stratification. In the absence 
of scientific support or statistical deriva-
tion, they claim that “an odds ratio of 3.0, 
or even of 2.0 depending on population 
allele frequencies” would be robustly 
interrogated by GWAS. The vast major-
ity of published GWAS loci therefore 
fall below the threshold for “popula-
tion stratification.” However, compared 
to candidate gene association studies, 
the beauty of whole-genome SNP data 
is that inflation of test statistics due to 
population substructure can be read-
ily identified and adjusted. Populations 
do not differ by just one or two SNPs; 
instead, they differ at many loci such that 
whole-genome data aid in identifying 
stratification, including extremely fine-
scale subpopulations among Europeans 
(Novembre et al., 2008). The GWAS com-
munity has established methods to deal 
with population stratification, and these 
methods effectively adjust for common 
variants without controversy. There are 
certainly challenges with the analyses of 
rare variants, hypervariable variants, or 
interrogation of recently admixed popu-
lations, which are all active topics of cur-
rent research. There are now standard 
practices to handle population stratifica-
tion in GWAS, such as genomic control, 
EigenStrat, and multidimensional scal-
ing. Furthermore, family-based study 
designs have the advantage of pro-
tecting against stratification. Thus, the 
GWAS community has developed ways 
to address population stratification, and 
odds ratios of 1.5, 1.2, or even 1.1 have 
proven to be bona fide signals rather than 
artifacts of population stratification.
The Essay’s authors go on to claim 
that the autism locus reported by our 
group (Wang et al., 2009) is a “false posi-
tive” due to population stratification, but 
the study was driven by family-based 
cohorts both at the discovery and repli-
cation stages, with case-control cohorts 
further supporting the finding. Here, 
McClellan and King ignore the fact that 
family-based analysis is robust against 
stratification and have mistakenly con-
sidered GWAS hits as “false positives” 
if allele frequencies varied across Euro-
pean or HapMap populations. For exam-
ple, they claim that our reported autism-
associated SNP, rs4307059 (Wang et 
al., 2009), was a “particularly dramatic 
example of the perils of cryptic popula-
tion stratification.” Their reasoning is that 
the frequency of the proposed risk variant 
varies from 0.21 to 0.77 across European 
populations and that it is monomorphic in 
African populations. However, they used 
data from the Human Genome Diver-
sity Project that examined 938 samples 
from 51 worldwide populations (Coop 
et al., 2009), including 7 samples from 
Tuscany (allele frequency = 0.77) and 15 
samples from Orkney (allele frequency = 
0.21). When dealing with whole-genome 
data, small sample sizes often lead to 
biased estimates of allele frequencies, 
which we have now proven to be the 
case in this instance. We queried the 
101 Tuscan samples included in the 
HapMap 3 project (http://www.sanger.
ac.uk/humgen/hapmap3) and found 
that the allele frequency is 0.41, which 
is very similar to what we reported for 
our European American cohort (0.39 
in Wang et al., 2009) and substantially 
different from 0.77 quoted by McClel-
lan and King. Furthermore, even if the 
allele frequency measures are accurate, 
McClellan and King should not claim this 
SNP as “hypervariable” without appro-
priate control experiments to compare 
it with other SNPs. They may not appre-
ciate that the vast majority of SNPs do 
have variable allele frequencies between 
populations; in fact, 44% of SNPs on the 
Illumina array (http://hgdp.uchicago.edu/
Browser_tracks/FST) have more extreme 
population divergence (measured by 
Fst values) than rs4307059. Similarly, 
another SNP, which has been replicated 
for its association with type 1 diabetes 
(Hakonarson et al., 2007) in over 20 inde-
pendent studies, is ranked in the 29th 
percentile for Fst value. As such, it is our 
interpretation that the authors took a ran-
dom SNP from the middle of a ranked list 
and inappropriately claimed it as a “par-
ticularly dramatic” example of “popula-
tion stratification.” Extending this further, 
we also wish to point out that replication 
of GWAS signals depends on many fac-
tors, including the power of the study, 
the sample ascertainment scheme or 
diagnostic criteria, and the heterogene-
ity of the study population (for example, 
sporadic versus familial cases). For neu-
ropsychiatric diseases, it is well known 
that replication can be difficult with small 
sample sizes, as is the case for the study 
specifically referred to by the authors 
(Weiss et al., 2009), which interrogated 
258 families with autism for replica-
tion that were not part of AGRE (Autism 
Genetic Resource Exchange). Never-
theless, the autism locus on 5p14.1 has 
been replicated in a family-based GWAS 
without case-control comparisons (Ma et 
al., 2009) and has been associated with 
communication-spectrum phenotypes 
through quantitative trait associations 
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in 7313 children from a UK birth cohort, 
eliminating concerns of population strati-
fication (St Pourcain et al., 2010).
Like McClellan and King, we expect 
that with the development of high-
throughput sequencing technologies, 
whole-genome sequencing will be an 
invaluable tool for the study of rare 
genetic variants contributing to com-
plex diseases. However, the apparent 
importance of rare variants does not 
discount the contribution of common 
variants; the concerns about population 
stratification should not be overstated 
and certainly should not be presented 
as an argument to discredit many pub-
lished GWAS signals with an odds ratio 
of less than 2. These sections within 
an otherwise excellent Essay must be 
countered so that Cell readers have a 
more balanced view of the current state 
of the field.
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In response to our Essay “Genetic Het-
erogeneity of Human Disease” (McClellan 
and King, 2010), Wang et al. and Klein et al. 
challenge our critique of GWAS findings. 
Both Correspondence suggest that our 
conclusions lack an understanding of the 
principles of the common variant-common 
disease model and its application in GWAS 
methodology. We respectfully disagree, 
and in fact our Essay directly addressed 
many of their points. We are happy to clar-
ify further. The issue is not ignorance of 
GWAS methodology; the issue is reconcil-
ing GWAS findings with population genet-
ics, evolution, and biology.
There is no dispute that common 
genetic variants influence human traits. 
Alleles with the strongest influences on 
human traits are associated with benign 
phenotypes, such as hair color and 
eye color, that vary across individuals. 
Alleles for these traits lie in coding and 
known regulatory regions (Hindorff et 
al., 2009). Such variants have been influ-
enced by selection in human evolution. 
Thus, the best documented common 
variants with a substantial impact on 
disease risk typically are associated with 
illnesses presenting later in life, includ-
ing Alzheimer’s disease (APOE), exfoliat-
ing glaucoma (LOXL1), and age-related 
macular degeneration (CFH). These 
alleles persist in the population because 
the associated illnesses do not nega-
tively influence reproductive fitness.
However, the existence of common 
alleles that truly influence disease does 
not imply that all GWAS findings are 
valid. To date, published GWAS have 
reported more than 500 single-nucle-
otide polymorphisms (SNPs) associated 
with various diseases and traits, 88% of 
which lie in introns or intergenic regions, 
and for which the median odds ratio for 
effect size is 1.33 (Hindorff et al., 2009). 
Few of these associations have biologi-
cal support.
In order to identify alleles that influence 
disease using GWAS, two fundamen-
tal criteria must be met: (1) a common 
variant influencing the trait in question 
must truly exist in the population being 
studied; and (2) the genotyped markers 
used in association analyses must either 
include the causal variant or be in link-
age disequilibrium (LD) with the causal 
variant in the population being stud-
ied. Common “risk SNPs” detected by 
GWAS could in theory be in LD with rare 
disease-causing alleles, if by chance 
rare causal alleles are disproportionately 
linked with a common variant (Dickson et 
al., 2010).
In addressing our critique, both 
Wang et al. and Klein et al. acknowl-
edge that GWAS methodologies are 
designed to detect SNPs primarily 
found in intergenic or intronic regions, 
given the construction of standard SNP 
arrays. They argue that the risk SNPs 
implicated by GWAS are not expected 
to be causal but instead are in LD with 
true causal variants. Wang et al. main-
tain that standard GWAS methodolo-
gies adequately control for population 
stratification. Further, they note that 
a large proportion of HapMap SNPs 
vary widely across populations, and 
therefore it is not surprising that highly 
variable SNPs emerge as risk vari-
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